BullFrog AI vs Vyome
BFRG and HIND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BFRG and HIND compare
Vyome is the larger company, worth 1.2 times as much as BullFrog AI ($10.7M against $9.0M).
BullFrog AI scores higher on the StockData Score (3 against 1 for Vyome), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BFRG | HIND |
|---|---|---|
| Size and price | ||
| Market cap | $9.0M | $10.7M |
| Share price | $0.488 | $1.53 |
| Change, 1 year | −51.2% | −69.0% |
| Change, 5 years | – | −100.0% |
| Beta (5Y) | 4.87 | 1.61 |
| Employees | 9 | 18 |
| StockData Score | ||
| Total score | 3 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 82.8× |
| P/B | 1.3× | – |
| Growth | ||
| Revenue growth (TTM) | – | −67.1% |
| Revenue growth, 5Y average | – | −51.0% |
| Profitability | ||
| Gross margin | – | 52.7% |
| Operating margin | – | −9190% |
| Net margin | – | −8717% |
| Return on equity | −131% (better) | −194% |
| Return on invested capital | – | −173% |
| Financial health | ||
| Interest coverage | −1105.4× | −285.8× (better) |
| Current ratio | 10.57 (better) | 4.37 |
| Altman Z-score | 1.34 (better) | −13.61 |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −111% | 40.0% (better) |
| Shareholder yield | −111% | 40.0% (better) |
| Ownership | ||
| Held by institutions | 7.5% | 2.0% |
| Held by insiders | 13.7% | 6.8% |
| Insider net buying, 12 months | $71.5K | – |
| Short interest, % of float | – | 0.28% |
Go deeper
- BFRG stock overview
- BFRG income statement
- BFRG valuation and score
- HIND stock overview
- HIND income statement
- HIND valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.